Klotho Neurosciences, Inc. announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery. Dr....
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Dehydrated Alcohol Injection, USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended its...
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be impacting as many as 1 in 3 people globally. C15:0...
Neurocrine Biosciences, Inc. announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with...
Kashiv BioSciences, LLC announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The randomized, double-blind, multicenter study...
The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult...
Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)....
Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset,...
NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present...
ZEISS demonstrates a new standard for the future of ophthalmic research at the Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS RDP),...
AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals Cleveland, and Eli Lilly and Company, recently conducted a detailed post-hoc analysis of Lilly’s SURPASS-3 trial. The...
Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...
Xencor, Inc.a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942. A high-potency,...
Creyon Bio, Inc. announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as...
Labcorp a global leader of innovative and comprehensive laboratory services, announced the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in...
Toenail fungus, medically known as onychomycosis, is more than just a cosmetic issue. It's a persistent condition that affects the appearance, health, and comfort of your feet. What begins as a small yellow or white spot under the nail can...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically...
Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia. The study is evaluating the use of Pykus' proprietary, lead product candidate, PYK-2101, a focal...
